ATAI Life Sciences N.V.

Germany

ATAI

@atai_life Website

BTC Holdings

Total P&L

Total profit/loss on Bitcoin holdings

+29.33%

Total profit/loss on Bitcoin holdings

Average Cost per BTC

Average price paid for each Bitcoin

$86,207

Average price paid for each Bitcoin

Share Price

Current trading price per share

$4.61

Current trading price per share

Market Cap

Total market capitalization

$987M

Total market capitalization

Enterprise Value

Market cap plus debt minus cash

$951M

Market cap plus debt minus cash

NAV Multiple

Net Asset Value multiplier

152.64

Net Asset Value multiplier

BTC / Market Cap

Bitcoin holdings as % of market cap

0.7%

Bitcoin holdings as % of market cap

About ATAI Life Sciences N.V.

ATAI Life Sciences N.V., listed on Nasdaq with the ticker ATAI, is a clinical-stage biopharmaceutical company headquartered in Berlin, Germany. Founded in 2018, it emerged to address unmet needs in mental health through innovative therapies. Its business model centers on a decentralized platform that incubates and advances psychedelic-inspired compounds and digital therapeutics. Core operations involve developing treatments for disorders like depression, anxiety, and addiction, leveraging partnerships with subsidiaries to accelerate research, clinical trials, and regulatory pathways.

The company integrates Bitcoin into its treasury strategy, holding it as a reserve asset to diversify its financial portfolio and hedge against inflation. This reflects a forward-thinking approach to corporate finance amid economic uncertainties. Beyond treasury management, ATAI explores broader digital asset strategies, including potential blockchain applications for secure data handling in clinical research and patient privacy, aligning with its mission to innovate in healthcare delivery.

Led by CEO Florian Brand and Chairman Christian Angermayer, a visionary in biotech and finance, ATAI maintains a prominent industry presence with a robust pipeline of psychedelic therapies. Its leadership drives collaboration across academia and industry, positioning ATAI as a leader in mental health innovation. By combining cutting-edge science with strategic financial tools, ATAI ensures long-term relevance in transforming global healthcare.